Mouse double minute 4 (MDM4) as a member of MDM family, is an
oncogene emerging as an imperative negative regulator of p53. Tumor suppressor
protein p53 plays a crucial role in cell cycle arrest, apoptosis and homeostasis. It has
been reported that frequent inactivation of p53 was observed in numerous human
cancers including hematologic malignancies. MDM4, the newly discovered modulator
of p53 protein, is frequently amplified in various solid tumors such as cutaneous
melanoma, retinoblastoma and hematological malignances such as chronic lymphocytic
leukemia, acute myeloid leukemia and mantle cell lymphoma. Multiple evidences implicate that over-expression of
MDM4 is associated with tumor progression and poor prognosis which can be reversed by knockdown of MDM4
expression or restoration of p53 function, and support the rationale for the design of future MDM4-specific therapeutics.
This article discusses and focuses on using MDM4 as a novel biomarker as well as a therapeutic target for hematologic
Keywords: Biomarker, hematologic malignancies, MDM2, MDM4, p53, therapeutic approach.
Rights & PermissionsPrintExport